RxDoctor Payments Data

Alex Nester, MD

Hematology · Omaha, NENPI 1427498815

Payments from drug & device makers

$2,377in general payments, 2019–2025

Across 17 payments — averaging $139.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$1K
  • Bristol Myers Squibb$750
  • AstraZeneca$142
  • Pfizer$90
  • Incyte Corporation$76
  • Novartis$76
  • plus $80 from 4 others

What the payments were for

  • Consulting fees$1,13648%
  • Speaking & faculty fees$75032%
  • Food & beverage$38016%
  • Education$1105%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology providers in Nebraskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$37,471
Medicare patients
205
Services billed
378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide14$232,238
DopteletAvatrombopag Maleate13$213,353
CalquenceAcalabrutinib Maleate12$126,805
PromactaEltrombopag Olamine11$81,304
Deferasirox14$74,275
EliquisApixaban75$70,365
XareltoRivaroxaban19$20,466
OxycontinOxycodone Hcl13$4,247
Danazol13$2,214
Hydroxyurea25$787
Oxycodone Hcl46$664
Tranexamic Acid13$660
Gabapentin19$386
Morphine Sulfate ErMorphine Sulfate11$311
Celecoxib11$262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$750$232,23814 claims
AstraZenecaCalquence$142$126,80512 claims
NovartisPromacta$76$81,30411 claims
PfizerEliquis$90$70,36575 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Nebraskaon file to place this against a meaningful peer group, so we don't.

Other hematology in Omaha

Where these figures come from

Is this you, or does something look wrong? →